BENZPHETAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Benzphetamine Hydrochloride patents expire, and when can generic versions of Benzphetamine Hydrochloride launch?
Benzphetamine Hydrochloride is a drug marketed by Avet Lifesciences, Chartwell, Epic Pharma Llc, Impax Labs, Kvk Tech, Scinopharm Taiwan, Specgx Llc, and Tedor Pharm. and is included in nine NDAs.
The generic ingredient in BENZPHETAMINE HYDROCHLORIDE is benzphetamine hydrochloride. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the benzphetamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Benzphetamine Hydrochloride
A generic version of BENZPHETAMINE HYDROCHLORIDE was approved as benzphetamine hydrochloride by KVK TECH on July 20th, 2010.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BENZPHETAMINE HYDROCHLORIDE?
- What are the global sales for BENZPHETAMINE HYDROCHLORIDE?
- What is Average Wholesale Price for BENZPHETAMINE HYDROCHLORIDE?
Summary for BENZPHETAMINE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 1,776 |
| DailyMed Link: | BENZPHETAMINE HYDROCHLORIDE at DailyMed |
Pharmacology for BENZPHETAMINE HYDROCHLORIDE
| Drug Class | Sympathomimetic Amine Anorectic |
| Physiological Effect | Appetite Suppression Increased Sympathetic Activity |

